Background: Little is known about the long-term efficacy and safety of canakinumab in
paediatric FMF patients. Aim: To present the single centre experience of colchicine-resistant …

Background: Little is known about the long-term efficacy and safety of canakinumab in
paediatric FMF patients. Aim: To present the single centre experience of colchicine-resistant …

Background It has been reported that canakinumab, a monoclonal anti IL-1 antagonist, was
effective in patients with FMF who are either non-responsive or intolerant to colchicine …

Objectives There is no consensus on canakinumab treatment tapering and discontinuation
strategies in colchicine-resistant FMF patients. In this study, we aimed to establish a …

Abstract Introduction Familial Mediterranean fever (FMF) is an autoinflammatory disease
characterized by interleukin (IL)-1 overproduction. Colchicine is the mainstay drug in the …

Familial Mediterranean fever (FMF) is the most common monogenic auto-inflammatory
disease characterized by recurrent attacks of fever and serositis. Although colchicine is the …

Objective. To determine the feasibility of withdrawing canakinumab (CAN) in a large cohort
of paediatric patients with colchicine-resistant familial Mediterranean fever (crFMF) …

Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory
disease, is characterized by recurrent self-limited attacks of fever and serositis. Between 5 …

Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial
Mediterranean Fever (FMF) patients. Sixty-five patients with FMF who received …

Objective We aimed to present our single-center real-life experience of canakinumab use in
adult patients with familial Mediterranean fever (FMF). Methods Data were derived from the …